BBIO - BridgeBio Pharma GAAP EPS of -$0.92 misses by $0.07 revenue of $1.87M misses by $3.05M
- BridgeBio Pharma press release ( NASDAQ: BBIO ): Q4 GAAP EPS of -$0.92 misses by $0.07 .
- Revenue of $1.87M (-85.5% Y/Y) misses by $3.05M .
- Cash, cash equivalents, marketable securities and restricted cash (current), totaled $466.2 million as of December 31, 2022, compared to $787.7 million as of December 31, 2021.
For further details see:
BridgeBio Pharma GAAP EPS of -$0.92 misses by $0.07, revenue of $1.87M misses by $3.05M